{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:57:34Z","timestamp":1760623054968,"version":"3.37.3"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction and objective<\/jats:title><jats:p>Sarcoidosis is a systemic granulomatous disease predominantly affecting the lungs, although granulomas can also involve all other organs. Fortunately, it is often a self\u2010limiting disease and aggressive treatment is not indicated in majority of cases. However, treatment is recommended when critical organs are affected or the disease is progressive. So far, there is lack of reliable information regarding the frequency of treatment in Caucasian population or data are discordant. The aim of this study was to evaluate the prevalence of systemic immune\u2010modulating treatment in a large cohort of sarcoidosis patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective analysis of patients discharged from our institution with the final diagnosis \u2018sarcoidosis\u2019 (ICD\u201010: D86) from January 2010 to December 2013.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1810 sarcoidosis patients were hospitalized during these four years, 47.6% were females, mean age was 43.5\u2009\u00b1\u200912.2 years. The majority (80.6%) were discharged as pulmonary and\/or lymph node sarcoidosis (D86.0, D86.1, D86.2). Only 281 (15.5%) patients were discharged with systemic treatment, 60.1% of them were men (OR 1.5; 95% CI: 1.1\u20101.9, <jats:italic>P<\/jats:italic>\u2009=\u2009.0047). The 44.8% of patients who had sarcoidosis also involving an organ other than the lungs (D86.8) were much more likely to be treated: OR 5.6; 95% CI: 4.2\u20107.4, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.0001). Older age (&gt;50) was also identified as a risk factor for treatment (odds ratio: 1.8; 95% CI: 1.5\u20102.4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Less than 16% sarcoidosis patients required systemic treatment. Older men with multiorgan sarcoidosis were more likely to be treated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/crj.12664","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T15:17:01Z","timestamp":1500563821000},"page":"1367-1371","source":"Crossref","is-referenced-by-count":6,"title":["Systemic treatment for sarcoidosis was needed for 16% of 1810 Caucasian patients"],"prefix":"10.1111","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-757X","authenticated-orcid":false,"given":"Magdalena M.","family":"Martusewicz\u2010Boros","sequence":"first","affiliation":[{"name":"3<sup>rd<\/sup> Lung Diseases Department National TB &amp; Lung Diseases Research Institute Warsaw 01\u2010138 Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr W.","family":"Boros","sequence":"additional","affiliation":[{"name":"Lung Pathophysiology Department National TB &amp; Lung Diseases Research Institute Warsaw 01\u2010138 Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Wiatr","sequence":"additional","affiliation":[{"name":"3<sup>rd<\/sup> Lung Diseases Department National TB &amp; Lung Diseases Research Institute Warsaw 01\u2010138 Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Fijo\u0142ek","sequence":"additional","affiliation":[{"name":"3<sup>rd<\/sup> Lung Diseases Department National TB &amp; Lung Diseases Research Institute Warsaw 01\u2010138 Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Roszkowski\u2010\u015ali\u017c","sequence":"additional","affiliation":[{"name":"3<sup>rd<\/sup> Lung Diseases Department National TB &amp; Lung Diseases Research Institute Warsaw 01\u2010138 Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.ats4-99"},{"issue":"1","key":"e_1_2_10_3_1","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson MA","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.3.623"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.12.009"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.84"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000078"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000052"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/18715281113126660062"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8492-9"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"52","article-title":"The late follow\u2010up of chronic sarcoid patients previously treated with corticosteroids","volume":"15","author":"Rizzato G","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"2","key":"e_1_2_10_12_1","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson MA","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.3.238"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcl038"},{"issue":"1","key":"e_1_2_10_15_1","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman RP","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"3","key":"e_1_2_10_16_1","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson MA","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.2.424"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1598"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.10.2104046"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00075307"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009096"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(97)70070-X"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-015-9805-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1376401"},{"issue":"1","key":"e_1_2_10_25_1","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman RP","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1728"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e3283642a7a"},{"issue":"1","key":"e_1_2_10_28_1","first-page":"87","article-title":"Efficacy of azathioprine as second\u2010line treatment in pulmonary sarcoidosis","volume":"16","author":"Lewis SJ","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.14511179"},{"issue":"2","key":"e_1_2_10_30_1","first-page":"91","article-title":"Practical eminence and experience\u2010based recommendations for use of TNF\u2010alpha inhibitors in sarcoidosis","volume":"31","author":"Drent M","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202891"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcrj.12664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.12664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/crj.12664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.12664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T16:21:46Z","timestamp":1693844506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/crj.12664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/crj.12664"],"URL":"https:\/\/doi.org\/10.1111\/crj.12664","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"type":"print","value":"1752-6981"},{"type":"electronic","value":"1752-699X"}],"subject":[],"published":{"date-parts":[[2017,8,2]]}}}